Femasys (NASDAQ:FEMY) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Femasys (NASDAQ:FEMY) from a sell rating to a hold rating in a report issued on Saturday morning.

Several other research firms have also commented on FEMY. Laidlaw started coverage on shares of Femasys in a research report on Thursday, November 20th. They set a “buy” rating and a $6.50 price target for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Femasys in a report on Thursday, January 22nd. Finally, Lake Street Capital began coverage on shares of Femasys in a research note on Tuesday, March 3rd. They set a “buy” rating and a $1.50 price target on the stock. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $5.50.

Femasys Stock Up 0.4%

Femasys stock opened at $0.53 on Friday. Femasys has a one year low of $0.31 and a one year high of $1.76. The stock has a fifty day moving average of $0.57 and a 200 day moving average of $0.62. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.61 and a current ratio of 1.16. The stock has a market cap of $30.99 million, a PE ratio of -0.74 and a beta of -2.53.

Hedge Funds Weigh In On Femasys

Several large investors have recently added to or reduced their stakes in FEMY. Geode Capital Management LLC lifted its stake in shares of Femasys by 50.8% during the 4th quarter. Geode Capital Management LLC now owns 389,280 shares of the company’s stock valued at $224,000 after buying an additional 131,052 shares in the last quarter. Banco BTG Pactual S.A. purchased a new stake in Femasys in the 4th quarter worth $88,000. Jane Street Group LLC bought a new stake in Femasys during the fourth quarter valued at about $62,000. State Street Corp raised its holdings in Femasys by 43.5% during the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after acquiring an additional 24,500 shares during the period. Finally, Cetera Investment Advisers purchased a new position in shares of Femasys in the fourth quarter valued at about $36,000. Hedge funds and other institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.